Division of Hematology/Oncology

Faculty

faculty photo

Patrick F Fogarty, MD

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Director, Penn Comprehensive Hemophilia and Thrombosis Program, Philadelphia, PA
Hematologist, Penn Presbyternian Medical Center
Medical Director, Penn Blood Disorders Clinic, Division of Hematology/Oncology
Hematologist, Children's Hopsital of Philadelphia
Department: Medicine

Contact information
Division of Hematology/Oncology
Penn Blood Disorders Center
3rd Floor Dulles Building
3400 Spruce Street
Philadelphia, PA 19104
Office: 215-615-6555
Fax: 215-615-6599
Education:
B.A.
University of Pennsylvania, 1992.
M.D. (Medicine)
Jefferson Medical College, 1996.
Post-Graduate Training
Intern, Georgetown University Medical Center, Washington, DC, 1996-1997.
Resident in Medicine, Georgetown University Medical Center, Washington, DC, 1997-1999.
Fellowship in Hematology, National Heart, Lung & Blood Institute, National Institutes of Health, Bethesda, MD, 1999-2002.
Clinical Research Fellowship, Warren Grant Magnuson Clinical Center, Hematology Section, National Institutes of Health, 2002-2004.
Certifications
American Board of Internal Medicine (Internal Medicine), 1999.
American Board of Internal Medicine (Hematology), 2002.
American Board of Internal Medicine (Medical Oncology), 2003.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Fogarty PF, Powell J, Kruse-Jarres R, Lin J, Mahlangu J, Perry D, McRae S, Potts J, Li S, Brennan A, Pierce G: Analysis of baseline characteristics and 5-day dosing interval with rFVIIIFc in the phase 3 A-LONG study. 2014 Symposium of the Thrombosis & Hemostasis Summit of North America (THSNA), Chicago, IL. Poster presentation. April 2014.

PF Fogarty, T Minichiello: Disorders of Hemostasis, Thrombosis, & Antithrombotic Therapy. Current Medical Diagnosis and Treatment, 53rd Edition. SJ McPhee, MA Papadakis (eds.). McGraw Hill, Page: pp 520-546, 2014.

Fogarty, Patrick.: "Maintaining a Good Relationship with Your Hemophilia Treatment Center" (Patient Education Video, Department of Continuing Medical Education, Keck School of Medicine at the University of Southern California). Youtube. 2014.

James, P., Kasthuri, R., Kruse-Jarres, R., Soni, A., Kulkarni, R., Bidlingmaier, C., Chitlur, M., Fogarty, P., Gomez, K., Holm, P. A., Mahlangu, J., Mancuso, M. E., Mingot-Castellano, M. E., Dolan, G.: Global Emerging HEmophilia Panel (GEHEP): A Multinational Collaboration for Advancing Hemophilia Research and Treatment. Transfus Med Hemother 40(5): 352-5, October 2013.

Colace T, Panckeri K, Fogarty P, Diamond S.: A microfluidic model of in vitro hemostasis that potentiates thrombin generation via the intrinsic pathway of coagulation. International Society on Thrombosis and Haemostasis, XXIV Congress, Amsterdam. July 2013.

Li S, Neelakantan S, Powell J, Josephson N, Pasi J, Perry D, Shapiro A, Ragni M, Kulkarni R, Fogarty P, Brennan A, Vigilani G, Pierce G, Jiang H, Nestorov I.: Population pharmacokinetic analysis of long-lasting recombinant factor VIII Fc fusion protein (rFVIIIFc) in patients with severe haemophilia A International Society on Thrombosis and Haemostasis, XXIV Congress, Amsterdam. July 2013.

Lane J, McLaren PJ, Dorrell L, Shianna KV, Stemke A, Pelak K, Moore S, Oldenburg J, Alvarez-Roman MT, Angelillo-Scherrer A, Boehlen F, Bolton-Maggs PH, Brand B, Brown D, Chiang E, Cid-Haro AR, Clotet B, Collins P, Colombo S, Dalmau J, Fogarty P, Giangrande P, Gringeri A, Iyer R, Katsarou O, Kempton C, Kuriakose P, Lin J, Makris M, Manco-Johnson M, Tsakiris DA, Martinez-Picado J, Mauser-Bunschoten E, Neff A, Oka S, Oyesiku L, Parra R, Peter-Salonen K, Powell J, Recht M, Shapiro A, Stine K, Talks K, Telenti A, Wilde J, Yee TT, Wolinsky SM, Martinson J, Hussain SK, Bream JH, Jacobson LP, Carrington M, Goedert JJ, Haynes BF, McMichael AJ, Goldstein DB, Fellay J; NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI).: A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. Hum Mol Genet 22(9): 1903-10, May 2013.

Fogarty PF, Kessler CM: Hemophilia A and B. Consultative Hemostasis and Thrombosis. Kitchens CS, Konkle BA, Alving BM, Kessler CM (eds.). Saunders Elsevier, 4th edition, May 1 2013 Notes: Elsevier Science Health Science Division. Expert Consult - Online and Print.

Tarantino MD, Fogarty P, Mayer B, Vasey SY, Brainsky A.: Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia. Blood Coagul Fibrinolysis 24(3): 284-296, April 2013.

J. Mahlangu, J. Powell, M. Ragni, P. Chowdary, N. Josephson, I. Pabinger-Fasching, H. Hanabusa, N. Gupta, R. Kulkarni, P. Fogarty, D. Perry, A. Shapiro, J. Pasi, S. Krassova, H. Jiang, S. Li, S. Neelakantan, F. Greblikas, J. Goyal, J. Sommer, J. Dumont, A. Innes, K. Nugent, A. Brennan, A. Luk, G. Pierce : Phase 3 Clinical Study of Recombinant Factor FVIII Fc Fusion Protein (rFVIIIFc) Demonstrated Safety, Efficacy, and Improved Pharmacokinetics (A-LONG). European Association of Hemophilia and Allied Disorders, 6th Annual Congress, Warsaw, Poland. Haemophilia. 19(Suppl.2): 10-82, February 2013.

back to top
Last updated: 03/20/2014
The Trustees of the University of Pennsylvania
 

Clinical Briefings Blog Spot

Penn MD Forum title with Penn Medicine Shield and Twitter